Evidence map›Paper›PMID 30662639›Full record

ReviewAmerican journal of translational research2018

Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring.

Wenna Luo, Mingliang Rao, Jiayao Qu, Dixian Luo

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Evaluation of Monocarboxylate Transporter 4 (Frontiers in cell and developmental biology · 2021
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Wenna LuoSouthern Medical University, Chenzhou Center for Clinical Pathological Laboratory, National and Local Joint Engineering Laboratory for High-through Molecular Diagnosis Technology, Affiliated The First People's Hospital of Chenzhou Chenzhou 432000, China.
Mingliang RaoSouthern Medical University, Chenzhou Center for Clinical Pathological Laboratory, National and Local Joint Engineering Laboratory for High-through Molecular Diagnosis Technology, Affiliated The First People's Hospital of Chenzhou Chenzhou 432000, China.
Jiayao QuSouthern Medical University, Chenzhou Center for Clinical Pathological Laboratory, National and Local Joint Engineering Laboratory for High-through Molecular Diagnosis Technology, Affiliated The First People's Hospital of Chenzhou Chenzhou 432000, China.
Dixian LuoSouthern Medical University, Chenzhou Center for Clinical Pathological Laboratory, National and Local Joint Engineering Laboratory for High-through Molecular Diagnosis Technology, Affiliated The First People's Hospital of Chenzhou Chenzhou 432000, China.
Chenzhou First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the most common cancer in both the developing and developed countries, which has an unoptimistic outcome. As a result of high rates in mortality and considerable difficulties in treatment, early detection of lung cancer is thought as one of the potential solutions for this stigma. Tissue biopsy has been widely used for cancer diagnosis, but the invasive nature limits their application, especially when repeated biopsies are needed. Liquid biopsy, a minimally invasive procedure aiming to primarily analyze circulating tumor cells (CTCs) and/or circulating tumor DNA (ctDNA) for diagnosing and profiling cancer, has gained interest from oncologists and basic researchers. A great number of achievements in the field of liquid biopsy has been developed, thus liquid biopsy is more feasible in clinical practice than before. More importantly, liquid biopsy is being used, in addition to the diagnosis of lung cancer, to predict prognosis according to genetic alterations and monitor disease based on signature molecular markers. In this review, we briefly summarize techniques in liquid biopsy and focus on its applications in disease diagnosis, prognosis prediction, and condition monitoring of lung cancer.

Indexed as

liquid biopsyLung cancerprognosistreatment responses

Identifiers

PMID30662639
PMCPMC6325529
OpenAlexW2989084682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.